

# Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer

April 30 2019

---



Dr. Frans Erdkamp first author of abstract 158P\_PR 'Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02).' Credit: European Society for Medical Oncology

Continuous chemotherapy shows greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented at the ESMO Breast Cancer Congress 2019, 2-4 May, Berlin, Germany.

The phase III study randomised 420 patients with advanced HER2-negative breast cancer to either an intermittent schedule (four cycles - [treatment holiday](#) - another four cycles) or a continuous schedule comprised of the same eight cycles administered consecutively. Both first line treatment (paclitaxel plus bevacizumab) and second line treatment (capecitabine or non-pegylated liposomal doxorubicin) followed these schedules. These analyses report on secondary endpoints from the Stop&Go study, with the main endpoint for second-line being [progression-free survival](#) (PFS).

Dr. Frans Erdkamp from Zuyderland Medical Center—Sittard-Geleen, Netherlands, presented findings related to the survival benefits of continuous scheduling in both first- and second-line chemotherapy compared to intermittent therapy. "Our main focus in this analysis was on the efficacy of second-line treatment, although, interestingly, the updated overall survival results showed that for the whole population (those who received first line only, or first and second lines of treatment) the [survival](#) was better with continuous treatment as well," said Dr. Erdkamp.

Patients who started second line treatment (n=270; 131 vs. 139 in intermittent vs. continuous arms) demonstrated a median PFS in second line of 3.5 vs. 5.0 months respectively, with a hazard ratio (HR) of 1.04 (95%CI 0.69-1.57). The median combined first- and second-line PFS for this population was 14.6 vs. 16.6 months with a HR of 1.59 (95%CI 1.04—2.45).

The quality of life results were presented by Dr. Anouk Claessens, also from Zuyderland Medical Center—Sittard-Geleen, Netherlands. "In clinical practice, we see considerable variation in treatment strategies, so felt it would be helpful to conduct a trial investigating the effect on quality of life of scheduling with modern agents." Claessens hypothesised that treatment holidays incorporated into scheduling would benefit quality of life.

Quality of life was measured every 12 weeks during treatment and follow-up, using RAND-36 questionnaires specifically chosen for their relevance to normal life. The course of both the physical and mental quality of life scores for each sequencing arm were monitored and the difference in course was estimated between arms. Median follow-up was 11.3 months.

"With the physical quality of life scores, we saw a linear decline in the intermittent arm causing a clinically meaningful difference of 5.68 points at 24 months (p

Citation: Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer (2019, April 30) retrieved 19 April 2024 from <https://medicalxpress.com/news/2019-04-chemotherapy-outcomes-quality-life-advanced.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--